Corcept Therapeutics, Inc. (CORT)

Oncology Corporate Profile

Stock Performance

5.0000
-0.0900

HQ Location

149 Commonwealth Drive
Menlo Park, CA 94025

Company Description

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication.

Website: http://www.corcept.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
mifepristone (+ eribulin)progesterone receptor antagonistBreast cancerI
mifepristoneprogesterone receptor antagonistBreast cancerI

View additional information on product candidates here »

Source: http://www.corcept.com

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/18/2017 12:17 pm

5/12/2017 06:17 am

5/12/2017 06:17 am

5/12/2017 06:17 am

5/12/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 06:17 am

5/4/2017 06:17 am

5/3/2017 06:17 pm

5/1/2017 12:17 pm

5/1/2017 06:17 am

4/27/2017 06:17 am

4/24/2017 06:17 am